Ewha Med J.  2025 Apr;48(2):e22. 10.12771/emj.2025.00115.

Bridging science and policy in tuberculosis treatment through innovations in precision medicine, drug development, and cohort research: a narrative review

• Min J
• Andrade BB
• Kim JS
• Jeong Y

• KMID: 2567574
• DOI: http://doi.org/10.12771/emj.2025.00115

Abstract

Recent advancements in tuberculosis treatment research emphasize innovative strategies that enhance treatment efficacy, reduce adverse effects, and adhere to patient-centered care principles. As tuberculosis remains a significant global health challenge, integrating new and repurposed drugs presents promising avenues for more effective management, particularly against drug-resistant strains. Recently, the spectrum concept in tuberculosis infection and disease has emerged, underscoring the need for research aimed at developing treatment plans specific to each stage of the disease. The application of precision medicine to tailor treatments to individual patient profiles is crucial for addressing the diverse and complex nature of tuberculosis infections. Such personalized approaches are essential for optimizing therapeutic outcomes and improving patient adherence—both of which are vital for global tuberculosis eradication efforts. The role of tuberculosis cohort studies is also emphasized, as they provide critical data to support the development of these tailored treatment plans and deepen our understanding of disease progression and treatment response. To advance these innovations, a robust tuberculosis policy framework is required to foster the integration of research findings into practice, ensuring that treatment innovations are effectively translated into improved health outcomes worldwide.

Keyword

Drug-related side effects and adverse reactions; Iatrogenic disease; Precision medicine; Treatment outcome; Tuberculosis